Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
about
Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 VaccinationCholine Binding Proteins from Streptococcus pneumoniae: A Dual Role as Enzybiotics and Targets for the Design of New AntimicrobialsLong-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalisBurden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature reviewEffect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide.Modeling the impact of the 7-valent pneumococcal conjugate vaccine in Chinese infants: an economic analysis of a compulsory vaccination.Initial effects of the National PCV7 Childhood Immunization Program on adult invasive pneumococcal disease in Israel.Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese ChildrenSerotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected at a Chinese hospital from 2011 to 2013.A longitudinal study of streptococcus pneumoniae carriage in healthy children in the 13-valent pneumococcal conjugate vaccine eraCarriage of Streptococcus pneumoniae 3 years after start of vaccination program, the NetherlandsNanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in SaskatchewanGlobal prevailing and emerging pediatric pneumococcal serotypes.Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections.Use of the 13-valent pneumococcal conjugate vaccine in infants and young children.The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.Pneumococcal Colonization in the Familial Context and Implications for Anti-Pneumococcal Immunization in Adults: Results from the BINOCOLO Project in SicilyHospitalization rates for pneumococcal disease in Brazil, 2004 - 2006.Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in ChinaA public health and budget impact analysis of vaccinating at-risk adults and the elderly against pneumococcal diseases in GermanyCost–effectiveness of vaccinating adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Germany
P2860
Q26739685-797EAA1D-F02A-4023-B6EE-CAC39CE6AAD7Q26744448-3CA26606-4AB6-4E6F-B747-2BA90CF8D45CQ28728017-5E7BD8C3-FAE2-43DB-B29E-11870B424393Q28742681-2B7EC9D7-1A4C-42BA-8B52-5A7CCD713C62Q33525194-1480BFBE-F52C-4150-960D-08861D415FC3Q35066491-4DD337EA-4847-4A28-A4FD-E053AB5C1333Q35089126-05420CDE-C6F9-4FFA-8DEA-88FC164F26B5Q35091736-F6B245F6-7A43-47D9-8A27-F8CD1146501CQ35186834-B955580C-E4DE-4E3B-A397-F0AA4A39D69EQ35737956-D06C3727-2222-409F-9308-7CB198AE987EQ35887787-641A8125-2813-4BC5-8499-A4D06FFB7968Q36039569-743FB5CB-8B90-4DEB-988D-9B28487DF8FCQ36826926-8E826F4D-7994-44C8-BD19-27CEDAFC8E90Q37309269-2A2563B2-A80F-463C-B2AC-351C05F55E66Q37478339-7AE3A849-8B38-4227-8641-E945837B09A6Q37525620-3F3AB58F-E58E-4882-985A-BAAFF035730DQ37821484-BCDE3F05-EC86-4351-9974-635DA89F84F7Q37857254-CEB75F50-0F91-4545-95A5-CE0FD210B509Q37991405-13C945EA-E6B3-48FC-9570-928E6D31E96CQ38080478-E9431CCC-0E0A-4EF9-AAD9-3617D78F8295Q40379779-DE91605C-158A-46E2-9590-751EA08A53A2Q43962541-E09F0604-B672-4183-B1F7-AC4BAAC6B466Q57930051-067D7B6A-3B09-40F7-8656-A0331D53A0D6Q58286118-39A70B8C-E6B4-467B-BF90-CABB31788BC2Q58286129-1F48EBA4-63FD-42CE-B833-E89E31327F63
P2860
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@en
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@nl
type
label
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@en
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@nl
prefLabel
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@en
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@nl
P2860
P356
P1476
Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
@en
P2093
Markus Rose
Stefan Zielen
P2860
P304
P356
10.1586/ERV.09.78
P577
2009-10-01T00:00:00Z